Pliant Therapeutics announced new preclinical and clinical data for PLN-101095, a dual integrin inhibitor, at the 2026 Society for Immunotherapy of Cancer meeting. The data showed that blocking integrins αvβ8 and αvβ1 combined with anti-PD-1 therapy enhances immune response and tumor suppression, supporting ongoing Phase 1 trials in solid tumors including lung and renal cancers. Early biomarker results suggest PLN-101095 activates immune pathways that improve response to pembrolizumab. This advances Pliant’s efforts to develop treatments for immune checkpoint inhibitor-refractory cancers.
Pliant Therapeutics' new data presentation on PLN-101095 offers context for readers following health innovation. Of 150 priced Health-sector US stocks tradable on Pluang, 121 rose and 18 fell today. Notable movers include Immunovant Inc. at USD 33.50 with a 9.73% gain and ImmunityBio Inc. at USD 7.49 down 13.26%, as of Nov 09, 2026 19:41 WIB.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
